Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab Plus WBRT in Brain Metastases From NSCLC
NCT00872482Phase 2Terminated
- Sponsor
- YM BioSciences
- Start
- Apr 2009
- Primary completion
- Jun 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of nimotuzumab in brain metastases, non-small cell lung cancer (NSCLC), sponsored by YM BioSciences. Started Apr 2009; status: terminated.
02
Drugs
nimotuzumab
03
Conditions
brain metastasesnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00872482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00872482.